Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NODAGA-SNA014 is a diagnostic radiopharmaceutical agent under early clinical development for use in positron emission tomography (PET) imaging. It is designed as a radionuclide drug conjugate labeled with gallium-68 and utilizes the NODAGA chelator to target specific tumor types. The primary indication is for imaging of solid tumors such as gastroesophageal junction adenocarcinoma, pancreatic cancer, and stomach adenocarcinoma. Its mechanism of action is as an imaging agent; it does not exert therapeutic effects but enables visualization of disease sites through PET/CT scans. The developer and active organization associated with this compound is Suzhou SmartNuclide Biopharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-NODAGA-SNA014.